WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Chronic Kidney Disease in a Gout Arthritis Patient During a Flare

Denada Florencia Leona [a*]

[a] *Andalas University, Dr. Mohammad Hatta Limau Manis, Padang, 25163, Indonesia*

A B S T R A C T

Background. Chronic kidney disease (CKD) is a progressive condition characterized by a gradual decline in kidney function over time. It is commonly associated with comorbidities such as hypertension and diabetes, and can significantly impact the management of other conditions, including gout arthritis. Gout, caused by hyperuricemia, is often complicated by CKD due to the impaired renal excretion of uric acid. Managing acute gout flares in CKD patients is challenging due to limited therapeutic options and the increased risk of adverse effects.

Case Presentation. We report the case of a 58-year-old Caucasian male with a history of CKD (Stage 3), hypertension, type 2 diabetes mellitus, and recurrent gout arthritis. The patient presented with a severe gout flare, characterized by intense pain, redness, and swelling of the right first metatarsophalangeal joint. Laboratory results showed elevated serum uric acid levels, decreased glomerular filtration rate (GFR), and elevated serum creatinine. Initial management with low-dose colchicine and corticosteroids led to significant improvement in symptoms. The patient's gout was previously managed with allopurinol, but adherence issues due to gastrointestinal side effects were noted. A comprehensive treatment plan including medication adjustments, dietary counseling, and patient education was implemented, resulting in stable renal function and improved adherence to urate-lowering therapy.

Conclusion. This case highlights the complexities of managing gout flares in patients with CKD. Effective management requires a careful, individualized approach that balances efficacy and safety, taking into account the patient's renal function, comorbidities, and potential drug interactions. Low-dose colchicine and corticosteroids proved effective for acute symptom relief, while continued use of allopurinol with close monitoring and patient education improved long-term outcomes. Regular follow-up and adjustments to therapy are essential to prevent future flares and manage both gout and CKD effectively.

Keywords: Arthritis gout, Flare, Chronic Kidney Disease, Interplay

Introduction

Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of kidney function over time. It is defined by a persistent decline in the glomerular filtration rate (GFR) or evidence of kidney damage for three months or longer. CKD is categorized into five stages based on GFR, with Stage 3 indicating moderate kidney damage and a GFR between 30 and 59 mL/min/1.73 m². The condition is associated with numerous complications, including hypertension, cardiovascular disease, anemia, mineral and bone disorders, and metabolic acidosis. CKD affects approximately 10-15% of the adult population worldwide, with increasing prevalence due to the aging population and rising incidence of risk factors such as diabetes and hypertension. Diabetes mellitus is the leading cause of CKD, accounting for nearly 40% of cases, followed by hypertension. Other risk factors include glomerulonephritis, polycystic kidney disease, prolonged use of nephrotoxic medications, and a history of acute kidney injury.[1]

CKD results from a complex interplay of hemodynamic, inflammatory, and fibrotic processes that ultimately lead to nephron loss and renal function decline. Hyperfiltration and hypertrophy of remaining nephrons initially compensate for nephron loss, but over time, this adaptive mechanism contributes to further renal damage. Inflammatory mediators and profibrotic cytokines promote interstitial fibrosis and glomerulosclerosis, exacerbating kidney damage. The clinical presentation of CKD is often asymptomatic in the early stages. As kidney function declines, patients may develop symptoms such as fatigue, edema, hypertension, and electrolyte imbalances. In advanced stages, uremic symptoms such as nausea, vomiting, pruritus, and altered mental status may occur. Laboratory findings typically include elevated serum creatinine, reduced GFR, proteinuria, and abnormalities in electrolyte and acid-base balance.[2,3]

CKD is associated with a range of complications that impact patient morbidity and mortality. These include Cardiovascular Disease. CKD patients have a markedly increased risk of cardiovascular events, which is the leading cause of death in this population. Other complication is anemia, reduced erythropoietin production by the kidneys leads to anemia, contributing to fatigue and decreased quality of life. The third one is mineral and bone disorders, CKD disrupts calcium and phosphate homeostasis, leading to secondary hyperparathyroidism, bone disease, and vascular calcification. The next complication that can be occurred is electrolyte Imbalances, impaired renal excretion can result in hyperkalemia, hyperphosphatemia, and metabolic acidosis, requiring careful management.[4]

The primary goals in managing CKD are to slow disease progression, manage symptoms and complications, and prepare for renal replacement therapy if necessary[5,6]. This involves:

1. Blood Pressure Control: Achieving target blood pressure levels (<130/80 mmHg) using renin-angiotensin-aldosterone system (RAAS) inhibitors (e.g., ACE inhibitors or ARBs) to reduce proteinuria and slow CKD progression.
2. Glycemic Control: In diabetic patients, maintaining HbA1c levels below 7% to prevent further renal damage.
3. Dietary Modifications: Reducing sodium, potassium, and phosphate intake, and protein restriction to alleviate symptoms and slow disease progression.
4. Management of Complications: Addressing anemia, bone and mineral disorders, and cardiovascular risk factors through appropriate pharmacological and non-pharmacological interventions.

CKD and gout frequently coexist, as impaired renal function can lead to decreased excretion of uric acid, resulting in hyperuricemia and gout flares. Managing gout in CKD patients is challenging due to limited treatment options and the increased risk of adverse effects[7]. This case report discusses the complexities of treating acute gout flares in a CKD patient, focusing on therapeutic strategies and patient outcomes.

Case Presentation

A 58 years-old male came to the emergency room with the chief complaint of severe pain, redness, and swelling in the left first metatarsophalangeal joint. The patient reported a sudden onset of excruciating pain in his left big toe, which he rated as 8/10 on the visual analog scale. The pain began two days prior to presentation and was associated with significant swelling and erythema. The patient had a history of similar episodes but noted this flare as particularly severe. The patient had been administered Losartan, metformin, allopurinol (100 mg daily), amlodipine by his internist. The patient admitted to inconsistent use of allopurinol due to gastrointestinal side effects, which led to lapses in urate-lowering therapy. The patient is an office worker. He got diagnosed 5 years ago for chronic kidney disease, likely secondary to hypertension and diabetes. He also had Hypertension that was managed with losartan and amlodipine. He had type 2 Diabetes Mellitus, Controlled with metformin. He also had recurrent flares over the past 10 years, previously managed with allopurinol and dietary modifications.

Physical Examination showed Vital signs were blood pressure 140/85 mmHg, Pulse: 78 bpm, Respiratory rate 16 breaths/min, Temperature 37.2°C. Joint Examination showed swelling, warmth, and erythema over the left first metatarsophalangeal joint with limited range of motion due to pain. Laboratory Tests showed that Serum Uric Acid was 10.5 mg/dL (normal range: 3.5-7.2 mg/dL), Serum Creatinine was 2.0 mg/dL (eGFR: 40 mL/min/1.73 m²), C-Reactive Protein (CRP) was Elevated, indicating inflammation. Complete Blood Count (CBC) was WBC count mildly elevated. Liver Function Tests was Within normal limits. Imaging showed X-ray of the Affected Joint showed soft tissue swelling without bony erosions or tophi. Synovial Fluid Analysis in Aspiration, there was Clear fluid obtained. Microscopy analysis showed the presence of monosodium urate crystals confirmed the diagnosis of gout. The primary diagnosis of the patient was acute gout arthritis flare in a patient with chronic kidney disease. While the Secondary Diagnoses were Hypertension and type 2 diabetes mellitus.

Acute Management in this patient were Initiated low-dose colchicine (0.6 mg once daily) considering the patient's renal impairment. High-dose colchicine was avoided due to the risk of toxicity. Prednisolone (20 mg daily) was prescribed for five days to control inflammation, followed by a tapering dose over the next week. Long-term Management for this patient were continued allopurinol at the same dose (100 mg daily) with an emphasis on adherence. Discussed potential strategies to manage gastrointestinal side effects, such as taking the medication with food. Educated the patient on dietary modifications to reduce purine intake and encouraged hydration to prevent uric acid crystallization. Regular follow-up appointments were scheduled to monitor renal function, serum uric acid levels, and blood pressure. Short-term Follow-up showed after 48 hours of initiating treatment, the patient reported a significant reduction in pain and swelling. By the end of the prednisolone tapering period, the patient experienced complete resolution of the gout flare. Long-term Follow-up showed at a two-week follow-up, serum uric acid levels had reduced to 7.8 mg/dl. The patient reported improved adherence to allopurinol with no significant gastrointestinal side effects. Renal function remained stable with serum creatinine levels at 2.0 mg/dL and eGFR at 40 mL/min/1.73 m². Blood pressure was well-controlled with continued antihypertensive therapy. The patient was advised to maintain regular follow-up visits every three months to monitor his condition and adjust therapy as necessary.

Discussion

This case highlights several important aspects of managing acute gout flares in patients with chronic kidney disease (CKD). The coexistence of these conditions presents a unique set of challenges, requiring careful consideration of pharmacological options and the patient's overall health status.[8]

Pathophysiology and Interrelationship of CKD and Gout[9]

- Uric Acid and Renal Function: CKD impairs the kidneys' ability to excrete uric acid, leading to hyperuricemia and subsequent gout flares. The decreased glomerular filtration rate (GFR) in CKD patients means that urate crystals are more likely to accumulate in the joints, triggering inflammatory responses.

- Inflammation and Disease Progression: Chronic inflammation from recurrent gout flares can contribute to further renal damage, creating a vicious cycle. Elevated uric acid levels have been implicated in promoting hypertension and cardiovascular disease, which are common comorbidities in CKD patients.

Pharmacological Considerations[10]:

- Colchicine: In this case, low-dose colchicine was chosen due to its relative safety in patients with renal impairment. High doses of colchicine can lead to toxicity, manifesting as gastrointestinal symptoms, bone marrow suppression, and neuromuscular complications. Monitoring for adverse effects is crucial, especially in CKD patients who are at higher risk.
- Corticosteroids: Prednisolone provided rapid relief of inflammation and pain. Steroids are a preferred option in CKD patients as they do not have nephrotoxic effects. However, they must be used with caution in diabetic patients due to their potential to elevate blood glucose levels.
- Allopurinol: Despite the patient's initial non-compliance due to gastrointestinal side effects, continuing allopurinol was critical for long-term management of hyperuricemia. Dose adjustments and patient education helped improve adherence. Alternative urate-lowering therapies, such as febuxostat, could be considered if allopurinol is not tolerated.

Non-Pharmacological Management[11]:

- Dietary Modifications: Educating the patient on reducing intake of purine-rich foods and alcohol, increasing hydration, and maintaining a balanced diet can help manage uric acid levels. Avoiding foods high in fructose and reducing sugar intake are also beneficial.
- Weight Management and Physical Activity: Encouraging regular exercise and weight loss can help reduce the frequency and severity of gout flares. Obesity is a known risk factor for both gout and CKD progression.
- Patient Education and Adherence: This case underscores the importance of educating patients on the chronic nature of gout and the need for consistent medication use to prevent flares. Addressing side effects and providing strategies to manage them can improve adherence.

Monitoring and Follow-up[12,13]:

- Regular Laboratory Monitoring: Periodic assessment of serum uric acid levels, renal function tests, and liver function tests are necessary to monitor the effectiveness and safety of treatment. Adjustments to therapy should be based on these results.
- Assessing for Complications: CKD patients with gout are at risk for developing tophi, chronic joint damage, and kidney stones. Regular clinical evaluations can help detect these complications early and manage them appropriately.

Clinical Implications and Future Directions[14,15]:

- Individualized Treatment Plans: Each patient's treatment plan should be individualized, considering their comorbidities, renal function, and response to therapy. Multidisciplinary approaches involving nephrologists, rheumatologists, and primary care physicians can optimize patient outcomes.
- Emerging Therapies: New therapeutic options, such as biologics targeting interleukin-1 (IL-1) inhibitors (e.g., anakinra) and uricase agents (e.g., pegloticase), offer potential benefits for patients with refractory gout and those with significant renal impairment. However, their use should be carefully evaluated in the context of each patient's overall health status.
- Research and Guidelines: Ongoing research into the pathophysiology of gout and CKD, as well as the development of updated clinical guidelines, can help improve the management of these conditions. Collaborative studies focusing on long-term outcomes of different therapeutic strategies are needed.

Conclusion

This case illustrates the complexities of managing acute gout flares in a patient with chronic kidney disease (CKD). The interplay between hyperuricemia and impaired renal function necessitates a tailored approach to treatment, considering both efficacy and safety. The successful resolution of the patient's acute gout flare was achieved through a strategic combination of low-dose colchicine and corticosteroids, demonstrating the importance of selecting appropriate pharmacological interventions in the context of renal impairment. Moreover, patient education on medication adherence and lifestyle modifications played a crucial role in long-term management. The case emphasizes the need for individualized treatment plans, regular monitoring, and a multidisciplinary approach to optimize outcomes for patients with concurrent gout and CKD. As new therapies and guidelines emerge, they will provide further opportunities to improve the management of these challenging conditions.

References

1. Neogi T. Gout. Ann Intern Med. 2016;165(1):ITC1-ITC16.
2. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricemia: An update. Expert Rev Clin Immunol. 2017;13(8):799-812.

3. Juraschek SP, Kovell LC, Miller ER III, et al. Association of kidney disease with treatment and outcomes of uric acid disorders in adults with gout. Arthritis Care Res (Hoboken). 2017;69(12):1931-1938.
4. Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2017;21(6):1305-1317.
5. Ponticelli C, Podestà MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 2020;98(2):279-280.
6. Safiri S, Kolahi AA, Cross M, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors in 195 countries and territories, 1990-2017: A systematic analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol. 2020;72(11):1916-1927.
7. Wen YK, Chen ML. The role of hyperuricemia in the progression of chronic kidney disease and the therapeutic effects of allopurinol. Exp Clin Endocrinol Diabetes. 2020;128(12):772-780.
8. So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120(6):1791-1799.
9. Bardin T, Bouée S, Clerson P, et al. Epidemiology of gout in the French population: Prevalence, comorbidities and treatment patterns. Joint Bone Spine. 2018;85(5):597-602.
10. Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879-895.
11. Köttgen A, Russell SD, Loehr LR, et al. Coexistence of chronic kidney disease and cardiovascular disease in the United States: The Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2008;52(4):598-607.
12. Singh JA, Cleveland JD. Gout and the risk of incident chronic kidney disease and progressive kidney function loss: A prospective cohort study. BMJ Open. 2018;8(6):e020736.
13. Grassi D, Ferri L, Desideri G, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-2438.
14. Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38.
15. Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout patients with moderate-to-severe renal impairment treated with febuxostat or allopurinol: A post hoc analysis of a randomized, double-blind, phase III study (CONFIRMS). Am J Ther. 2020;27(1):e76-e84